SS-31 / Elamipretide

Elamipretide localizes to the inner mitochondrial membrane and is studied for interactions with cardiolipin and mitochondrial membrane organization. The proposed result is improved electron-transport efficiency and reduced maladaptive oxidative stress, but the clinical relevance depends on disease, endpoint, and formulation.

In September 2025, FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg. Confirmatory studies are required. Other uses—including healthy aging, general energy, performance, and broad mitochondrial optimization—remain unapproved and investigational.

Barth syndrome predominantly affects males because it is X-linked, so the approved indication is not a general “male performance” claim. Female research remains relevant to other mitochondrial disorders, but efficacy cannot be inferred from the Barth syndrome approval.

FDA approval applies only to the specified product and indication. It does not validate research-market SS-31 products, wellness use, anti-aging claims, or combination missions with NAD+ or MOTS-C.

1. FDA accelerated approval announcement
2. FDA accelerated-approval obligations
3. Phase 3 nuclear-DNA mitochondrial disease trial
4. Friedreich ataxia investigator-initiated study